Viking Therapeutics (NASDAQ: VKTX) — Company Overview, News & Financial Data
Viking Therapeutics develops therapies for metabolic and endocrine disorders, focused on advancing treatment innovations.
Viking Therapeutics
Viking Therapeutics (NASDAQ:VKTX) is a biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Their portfolio consists of promising candidates aimed at treating conditions such as hypothyroidism, non-alcoholic fatty liver disease, and muscle wasting. Viking Therapeutics is dedicated to advancing these projects through clinical trials, with the ultimate objective of addressing unmet medical needs and improving patient lives. Through their rigorous research and innovative approach, they strive to develop effective treatments that can lead to better health outcomes for individuals affected by these disorders.
Snapshot
Operations
Products and/or services of Viking Therapeutics
- VK2809 is in development for lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis (NASH).
- VK5211, aimed at treating patients recovering from hip fractures by enhancing lean body mass and bone density.
- VK0214 targets X-linked adrenoleukodystrophy (X-ALD), a genetic disorder affecting the nervous system and adrenal glands.
- VK2735 is being explored for its potential in treating autoimmune diseases, offering a new approach to immune modulation.
- Development of a novel class of selective androgen receptor modulators (SARMs) for treating conditions associated with muscle and bone wasting.
- Research into thyroid beta agonists, exploring innovative treatments for metabolic and cardiovascular diseases.
Viking Therapeutics executive team
- Brian LianPresident, CEO & Director
- Gregory S. ZanteChief Financial Officer
- Michael MorneauVice President of Finance & Administration
- Katherine MercierVice President of Quality & Compliance
- Kenneth J. HermanSenior Vice President of Commercial, Marketing & Sales
- Geoffrey E. BarkerChief Development Officer
- Nils U. OlssonSenior Vice President of Technical Operations
- Hubert C. ChenChief Medical Officer
Latest news about Viking Therapeutics
Viking launches Phase 3 oral obesity trials
United StatesViking Therapeutics starts VK2735 maintenance trial
United StatesViking Therapeutics reports 22% placebo-adjusted weight loss in VK2735 obesity study
United StatesViking Therapeutics begins Phase 1 VK3019 obesity trial
United StatesViking obesity drug publication shows best-in-class potential
United StatesViking completes enrollment in study of flexible weight-loss dosing
United States
Key financials
Reported results for Viking Therapeutics, in USD.
- Market cap
- 3.2B
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -4.7
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -393.3M | -359.6M | |
| 0 | -150.9M | -110M | |
| 0 | -100.8M | -85.9M | |
| 0 | -70.4M | -68.9M |